Clinical Trials
5 trialsNCT03153410 2025-01-09
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Completed
NCT02265536 2024-10-28
A Study of LY3022855 In Participants With Breast or Prostate Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01346358 2024-09-19
A Study of IMC-CS4 in Subjects With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT03101254 2024-07-17
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT02718911 2023-10-16
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed